TOP > クイック検索 > 外国特許検索 > DRUG COMPLEX

DRUG COMPLEX

外国特許コード F170008956
整理番号 (S2015-1723-N0)
掲載日 2017年2月16日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP068934
国際公開番号 WO 2016208761
国際出願日 平成28年6月25日(2016.6.25)
国際公開日 平成28年12月29日(2016.12.29)
優先権データ
  • 特願2015-128028 (2015.6.25) JP
発明の名称 (英語) DRUG COMPLEX
発明の概要(英語) [Problem] To provide a drug delivery system that can deliver a drug into a cell expressing a VEGF receptor. [Solution] Provided is a VEGF binding peptide-drug complex which is incorporated into VEGF receptor-expressing cells by VEGF receptor endocytosis, by binding a drug to the C-terminal amino acid or the N-terminal amino acid of a VEGF binding peptide having a helix-loop-helix structure comprising an A block located on the N-terminal side comprising a peptide that forms an α-helix structure, a C block located on the C-terminal side comprising a peptide that forms an α-helix structure, and a B block comprising a peptide that connects the A block and C block by covalent bonds.
特許請求の範囲(英語) [claim1]
1. The helix which consists of the B block which consists of the peptide which ties C block and A block and C block where it consists of the peptide which forms ***A-heritsukusu structure and consist of the peptide which forms A block and the ***.alpha.-heritsukusu structure which are located on N terminal side and are located on C terminal side with covalent bond - the loop - the VEGF connection characteristic peptide which possesses helix structure and the VEGF connection characteristic peptide which the medicine connects - being the medicine mixture,
The aforementioned medicine, the amino acid of N end of the aforementioned VEGF connection characteristic peptide and/or directly or connects to the amino acid of C end indirectly,
The VEGF connection characteristic peptide which is taken in inside the VEGF receptor revelation cell by [endosaitosu] of the VEGF receptor - the medicine mixture.
[claim2]
2. As for the aforementioned medicine, at the connection style which can be cut off by the cell endoenzyme in the claim 1 section which is connected to the N terminal amino acid or C terminal amino acid of the aforementioned VEGF connection characteristic peptide the VEGF connection characteristic peptide of statement - the medicine mixture.
[claim3]
3. As for the aforementioned medicine, in the claim 1 which is connected to the condensation characteristic functional group which the amino acid of N end of the aforementioned VEGF connection characteristic peptide or the amino acid of C end has directly or 2 the VEGF connection characteristic peptide of statement - the medicine mixture.
[claim4]
4. As for the aforementioned condensation characteristic functional group, the thiol basis, the amino group, hydroxyl group, in the claim 1 which is either the carboxyl group or the aldehyde basis or 2 the VEGF connection characteristic peptide of statement - the medicine mixture.
[claim5]
5. The amino acid of N end of the aforementioned VEGF connection characteristic peptide and the amino acid of C end of particular VEGF connection characteristic peptide, directly or either of the claim 1-4 which is connected indirectly in 1 sections the VEGF connection characteristic peptide of statement - the medicine mixture.
[claim6]
6. The N terminal amino acid of the aforementioned A block and C terminal amino acid of the aforementioned B block, in the claim 5 which is connected with the linker which consists of 1- several amino acids the VEGF connection characteristic peptide of statement - the medicine mixture.
[claim7]
7. As for the aforementioned B block, either of the claim 1-6 which is the peptide which consists of each amino acid arrangement of statement in the arrangement number 3-6 in 1 sections the VEGF connection characteristic peptide of statement - the medicine mixture.
[claim8]
8. In the claim 7 which features that the aforementioned A block is the peptide which consists of the amino acid arrangement of statement in arrangement number 7, as for the aforementioned C block is the peptide which consists of the amino acid arrangement of statement in arrangement number 8 the VEGF connection characteristic peptide of statement - the medicine mixture.
[claim9]
9. The aforementioned A block to be the peptide which consists of the amino acid arrangement of statement in arrangement number 7, as for the aforementioned C block arrangement number 9 (KLXXLKXKLXXLKXAC: However, as for X the amino acid other than threonine, the alanine and the proline) in the claim 7 which is the peptide which consists of the amino acid arrangement of statement the VEGF connection characteristic peptide of statement - the medicine mixture.
[claim10]
10. In the claim 7 where the aforementioned A block is the peptide which consists of the amino acid arrangement of statement in arrangement number 7, as for the aforementioned C block is the peptide which consists of each amino acid arrangement of statement in the arrangement number 10-13 the VEGF connection characteristic peptide of statement - the medicine mixture.
[claim11]
11. The helix which consists of with the B block which consists of the peptide which ties C block and A block and C block where it consists of the peptide which forms ***A-heritsukusu structure and consist of the peptide which forms A block and the ***.alpha.-heritsukusu structure which are located on N terminal side and are located on C terminal side with covalent bond - the loop - being the VEGF connection characteristic peptide which possesses helix structure,
The amino acid of N end of particular VEGF connection characteristic peptide and/or the non annular VEGF connection characteristic peptide where the amino acid of C end has the condensation characteristic functional group of separation (however, those where each of them of N terminal amino acid and C terminal amino acid is a cystein are excluded).
[claim12]
12. The helix which consists of with the B block which consists of the peptide which ties C block and A block and C block where it consists of the peptide which forms ***A-heritsukusu structure and consist of the peptide which forms A block and the ***.alpha.-heritsukusu structure which are located on N terminal side and are located on C terminal side with covalent bond - the loop - being the VEGF connection characteristic peptide which possesses helix structure,
The amino acid of N end of particular VEGF connection characteristic peptide or the amino acid of C end to have the condensation characteristic functional group of separation, at the same time,
The N terminal amino acid of particular VEGF connection characteristic peptide and C terminal amino acid of particular VEGF connection characteristic peptide being bonded directly or indirectly, to annulation the VEGF connection characteristic peptide which is converted (however, the amino acid of N end and the amino acid of C end the VEGF connection characteristic peptide which is connected directly with SS connection is excluded).
[claim13]
13. The N terminal amino acid of the aforementioned VEGF connection characteristic peptide and C terminal amino acid of particular VEGF connection characteristic peptide, in the claim 12 which is connected with acid amide connection the VEGF connection characteristic peptide of statement.
[claim14]
14. The N terminal amino acid of the aforementioned A block and C terminal amino acid of the aforementioned C block, in the claim 12 which is connected with the linker which consists of 1- several amino acids the VEGF connection characteristic peptide of statement.
[claim15]
15. As for the aforementioned condensation characteristic functional group, the thiol basis, hydroxyl group, the amino group, either of the claim 11-14 which is either the carboxyl group or the aldehyde basis in 1 sections the VEGF connection characteristic peptide of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • OSAKA PREFECTURE UNIVERSITY
  • 発明者(英語)
  • FUJII IKUO
国際特許分類(IPC)
指定国 (WO2016208761)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close